The Morning Dispatch: Could a Roe Reversal Affect More than Just Abortion?

Happy Friday! The stock market had its worst day in nearly two years yesterday, one day after it had its best day in nearly two years. We’re not financial advisers, but unless you’re very close to retirement, we recommend just not checking your portfolio for a while.

Quick Hits: Today’s Top Stories

  • After formally recommending Moderna or Pfizer’s COVID-19 vaccine back in December, the Food and Drug Administration announced Thursday that—following a review of the risk of life-threatening blood clots—it will limit the authorized use of Johnson & Johnson’s shot to only people who can’t or won’t take other vaccines. The agency said it had confirmed 60 cases of thrombosis with thrombocytopenia syndrome (TTS)—including nine deaths—among millions who took the shot.

  • After a Wednesday New York Times piece reported that—according to anonymous U.S. officials—American intelligence has helped Ukraine’s military target and kill Russian generals, Pentagon press secretary John Kirby on Thursday said the U.S. isn’t doing so on purpose. “We do not provide intelligence on the location of senior military leaders on the battlefield or participate in the targeting decisions of the Ukrainian military,” Kirby said. Thursday evening, NBC News reported U.S. intelligence helped sink the Moskva, a key Russian battleship, according to anonymous U.S. officials.

  • OPEC announced Thursday it would increase its oil output by only 432,000 barrels per day in June, ignoring Western pleas to accelerate production and ease price pressure amid sanctions on Russian energy. OPEC is still following its plan to undo the production drops it implemented in 2020 when COVID-19 lockdowns curbed demand.

This content is available exclusively to Dispatch members
Try a membership for full access to every newsletter and all of The Dispatch. Support quality, fact-based journalism.
Already a paid member? Sign In
Comments (0)
Join The Dispatch to participate in the comments.

There are currently no responses to this article.
Be the first to respond.